Myasthenia gravis - current treatment standards and emerging drugs

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10128025" target="_blank" >RIV/00179906:_____/12:10128025 - isvavai.cz</a>
Alternative codes found
RIV/60162694:G44__/12:43874595 RIV/00216208:11160/12:10128025
Result on the web
<a href="http://www.intechopen.com/books/a-look-into-myasthenia-gravis/myasthenia-gravis-current-treatment-standards-and-emerging-drugs" target="_blank" >http://www.intechopen.com/books/a-look-into-myasthenia-gravis/myasthenia-gravis-current-treatment-standards-and-emerging-drugs</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5772/31127" target="_blank" >10.5772/31127</a>

Result language
angličtina
Original language name
Myasthenia gravis - current treatment standards and emerging drugs
Original language description
Myasthenia gravis is very rare disorder resulting from the autoimmune destruction of postsynaptic membrane in neuromuscular junction. In the most cases, antibodies bind to nicotinic acetylcholine receptors (nAChR), although other structures (e.g. musclespecific tyrosin kinase; MuSK) can be targeted as well.
Czech name
—
Czech description
—

Project
<a href="/en/project/GP203%2F09%2FP130" target="_blank" >GP203/09/P130: Development of novel acetylcholinesterase inhibitors as treatment of Myasthenia Gravis</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Result description